U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H15O9.Na
Molecular Weight 362.264
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESCULIN SODIUM

SMILES

[Na+].OC[C@H]1O[C@@H](OC2=C([O-])C=C3OC(=O)C=CC3=C2)[C@H](O)[C@@H](O)[C@@H]1O

InChI

InChIKey=ZVHOSRMJDHCBSF-QWFKVUSTSA-M
InChI=1S/C15H16O9.Na/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17;/h1-4,10,12-17,19-21H,5H2;/q;+1/p-1/t10-,12-,13+,14-,15-;/m1./s1

HIDE SMILES / InChI

Description

Esculin (Esculoside), a coumarin compound derived from the horse chestnut and the traditional Chinese herbs such as Cortex Fraxini, has long been used for treating inflammatory and vascular diseases. The main activities of Esculoside focus on capillary protection, as it improves capillary permeability and fragility. It is reported to inhibit catabolic enzymes such as hyaluronidase and collagenase, thus preserving the integrity of the perivascular connective tissue. Esculin has various biological activities including anti-oxidant activity, intestinal anti-inflammatory activity, anti-cancer activity and growth inhibition of human leukemia cells. Esculin inhibits lipid peroxidation and scavenges hydroxyl radicals in the rat liver and exerts anti-inflammatory activity in both carrageenan- and zymosan-induced paw edema in mice. Esculin has the gastroprotective effect in cold-restraint stress and pylorus ligation-induced ulcer models. Esculin is used in a microbiology laboratory to aid in the identification of bacterial species (especially Enterococci and Listeria).

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Palliative
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Esculoside
Primary
Unknown

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
twice a day for 60 days with a 3% O/W emulsion
Route of Administration: Transdermal
In Vitro Use Guide
To investigate the effect of the compounds on endothelial hyperpermeability in vitro, confluent human microvascular endothelial cells (HMEC-1) were pre-incubated in a Transwell insert with Esculin and the aglycone neoruscogenin (0.1 to 100 uM) for 30 min before the addition of thrombin (3 U/ml). Esculin (53.3%) reduced the thrombin induced permeability at 10 lM.